[go: up one dir, main page]

WO2024243197A3 - Method of treating patients with notch3 mutations - Google Patents

Method of treating patients with notch3 mutations Download PDF

Info

Publication number
WO2024243197A3
WO2024243197A3 PCT/US2024/030354 US2024030354W WO2024243197A3 WO 2024243197 A3 WO2024243197 A3 WO 2024243197A3 US 2024030354 W US2024030354 W US 2024030354W WO 2024243197 A3 WO2024243197 A3 WO 2024243197A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating patients
notch3
rho kinase
notch3 mutations
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/030354
Other languages
French (fr)
Other versions
WO2024243197A2 (en
Inventor
Thomas Macallister
Sven Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of WO2024243197A2 publication Critical patent/WO2024243197A2/en
Publication of WO2024243197A3 publication Critical patent/WO2024243197A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a method of treating patients with NOTCH3 mutation with rho kinase inhibitors. Aberrant NOTCH3 signaling is a pathological actor in small vessel cerebrovascular diseases, including CADASIL. A preferred aspect relates to treating patients orally with the rho kinase inhibitor fasudil or its active metabolite hydroxyfasudil.
PCT/US2024/030354 2023-05-24 2024-05-21 Method of treating patients with notch3 mutations Pending WO2024243197A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363503982P 2023-05-24 2023-05-24
US63/503,982 2023-05-24
US202363581786P 2023-09-11 2023-09-11
US63/581,786 2023-09-11

Publications (2)

Publication Number Publication Date
WO2024243197A2 WO2024243197A2 (en) 2024-11-28
WO2024243197A3 true WO2024243197A3 (en) 2025-01-16

Family

ID=93590382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/030354 Pending WO2024243197A2 (en) 2023-05-24 2024-05-21 Method of treating patients with notch3 mutations

Country Status (1)

Country Link
WO (1) WO2024243197A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183216A1 (en) * 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Notch3 agonist compositions and methods for treating small vessel diseases
WO2021257122A1 (en) * 2020-06-15 2021-12-23 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat vascular dementia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183216A1 (en) * 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Notch3 agonist compositions and methods for treating small vessel diseases
WO2021257122A1 (en) * 2020-06-15 2021-12-23 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat vascular dementia

Also Published As

Publication number Publication date
WO2024243197A2 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
EP4306529A3 (en) Fgfr inhibitors and methods of use thereof
CR20210132A (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
MX2023013082A (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease.
JP2012102137A (en) Method of treatment using eszopiclone
WO2023212612A3 (en) Certain chemical entities, compositions, and methods
NZ793376A (en) Crystalline ret inhibitor
MXPA05010958A (en) Indazole derivatives as jnk inhibitors.
NO20081843L (en) Pharmaceutical composition for improved cognitive function
PH12017502249A1 (en) Tofacitinib orally disintegrating tablets
WO2024243197A3 (en) Method of treating patients with notch3 mutations
MX2022015800A (en) Methods of using rho kinase inhibitors to treat vascular dementia.
GEAP202516743A (en) Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
JOP20220182A1 (en) FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
HUP0402577A2 (en) Indole derivatives as inhibitors of cytosolic phospholipase a2, process for producing them and pharmaceutical compositions containing them
WO2022268935A3 (en) Process for the preparation of nlrp3 inhibitors
MX2022012957A (en) Methods of using rho kinase inhibitors to treat alzheimer's disease.
WO2024015484A3 (en) Methods and systems for treating disease using an atr/chk1 signaling pathway inhibitor
MX2025001865A (en) Substituted pyridinone compounds as cbl-b inhibitors
WO2021164793A8 (en) Compound used as kinase inhibitor and use thereof
EP4223289C0 (en) MEDICINAL PRODUCT CONTAINING THE ADRB2 INHIBITOR ICI 118551 FOR THE TREATMENT OF PSORIASIS
MX2022015679A (en) TYK-2 INHIBITOR.
MX2024007062A (en) Heterocyclic compounds as dyrk1a inhibitors.
WO2025019309A3 (en) Compounds and compositions as c-kit kinase inhibitors
AU2021326530A8 (en) Dosage form compositions comprising an inhibitor of btk and mutants thereof
MX2024015988A (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis